AltPep's biomedical technology was developed at the University of Washington laboratory of AltPep Founder and CEO, Valerie Daggett, Ph.D., and targets the misfolded forms of amyloid proteins. This platform technology has the potential to transform the diagnosis and treatment of Alzheimer's Disease and other CNS-mediated disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/15/21 | $23,150,000 | Series A |
Alexandria Venture Investments Matrix Capital Management  | undisclosed |
| 06/22/23 | $52,900,000 | Series B |
Alexandria Venture Investments Eli Lilly and Company Matrix Capital Management Partners Investment Co. Section 32 Senator Investment Group | undisclosed |
